

Sampling, pharmacokinetics and logistics during ITI




Veronika Fiamoli

Dept. of Paediatric Haematology
Centre for Thrombosis and
Haemostasis
Children's University Hospital Brno,
Czech republic

Pharmacokinetics - definition

- Definiton:** *mathematical characterization of the process by which a drug is absorbed, distributed, metabolized, and eliminated by the body*



Recovery & Half-life

- Recovery:** a measure of the increase in plasma concentration (IU/dl) per injected dose (IU/kg) and is most often defined from the highest measured plasma concentration of FVIII/FIX within the first hour post-infusion
- Half-life:** the period of time required for the concentration or amount of drug in the body to be reduced to exactly one-half of a given concentration or amount (FVIII 12h /6-25h; FIX 18-34h)

Pharmacokinetics - target points



- **Wash out period:**
 - Hemophilia A: 72 hours or at least 48 hours
 - Hemophilia B: 72 hours up to 5 days
- **Dose of FVIII/FIX 50IU/kg**
- **Trough level >1 IU/dL = >1 % before ongoing administration of FVIII/FIX derivate within prophylaxis**

Pharmacokinetics - sampling




- **Hemophilia A**
 - < 30 min prior FVIII infusion
 - 7 time-points post infusion in older kids
 - 30min, 1, 3, 6, 12, 24, 48 hours
 - At least 5 time-points in patients ≤ 6 years old
- **Hemophilia B**
 - 7 samples over a period of 72 hours

ISTH recommendation

Inhibitor



- **Definiton:** antibody againts administred plasma derived/recombinant FVIII/FIX developing when the body's immune system stops accepting the factor as a normal part of blood
- **Reason of the difference in PK between hemophiliacs with and without inhibitor**



Inhibitor & Bethesda Units



- Low responder: 0,5 – 5 BU
- High responder: > 5BU

- 1 BU decreases the level of FVIII/FIX by 50%

Faster FVIII/FIX wash-out in patients with inhibitor

→ Faster FVIII/FIX wash-out in patients with inhibitor

Pharmacokinetics and ITI



- Useful when assessing whether a patient achieve full tolerance at the end of ITI



ITI monitoring



- **Inhibitor levels**
 - Start of ITI when inhibitor is lower than 10BU
 - To be monitored repeatedly (e.g. every 6 weeks)
- **Recovery**
 - Depending of the protocol (at least every 3 months)
- **Half-life**
 - Depending of the protocol (at least every 3 months)

When we could stop ITI



- **Hemophilia A**
 - Negative inhibitor titer
 - Recovery of more than 66%
 - Half-life greater than 7 hours
- **Hemophilia B**
 - No equivalent consensus on FIX half-life for the definition of tolerance

"Troubles" with ITI



Three different points of view

Patients

Parents

Hospital



Patients



- **Necessity of cooperation**
 - Small kids are afraid of more frequent drug administrations
 - Teenagers "don't like it at all"
- **Decreased quality of life**

Snímek 11

V1

Veronika; 27.3.2013

Parents




- **Necessity of cooperation**
 - Drug administration
 - at home
 - at the GP's
 - at Hematology Clinic
 - More frequent appointments at hematology
- **Concern for the child**
- **Changed quality of life**

Hospital – cost of care - disadvantages



- **Caring for people with inhibitors poses a special challenge.**
- **Overall medical treatment costs increased**
 - Increased usage of concentrates
 - Expensive bypassing agents
 - Potentially related healthcare – e.g. surgery
 - Patients with hemophilia who developed inhibitors are twice as likely to be admitted for a bleeding complication

Lower in-patient care costs – children's advantage



Quality of life – patients prospective



- Choose convenient i.v. access → frequent infusions
- Joint disease is more severe in these patients than in non-inhibitor patients *Morfini 2007*
- Chronic pain
- Days off-school and limitations in daily activities

Quality of life – small children



- Venous access can be painful and difficult
- 
- Frequent prophylactic treatment in younger children is compensated by better health-related QoL with fewer bleeding episodes later in life *Gringeri 2004*

Quality of life – teenagers



- QoL impairment is felt more in social domains compared to younger children
 - „feeling strange“ because they need frequent i.v. treatment
 - more often at the doctor's than their mates
 - less time spent with friends
 - limited in sport and other activities



Quality of life - parents



- Fear → Overprotection
- Necessity to learn new uncommon skills
- Absenteesm from work

└ Lower family income

Home treatment - advantages



- Better prevention of profuse bleeding by immediate treatment of incipient bleed
- Time and economic savings in terms of transportations to and from hospital, waiting time and days of treatment
- Reduced absence from school and work
- Helping patients to live independent and „normal“ life

Quality of life – doctors and nurses



- Comprehensive support system
 - Educational efforts
 - Infusion training
 - 24/7 availability of „over-the-phone“ or personal consultation
 - Psychological support for both children and parents

Quality of life - conclusion



- QoL in patients with inhibitor is impaired more than in healthy children or in non-inhibitor patients, but much better when comparing with the past times (70-90's)
- Cooperation between patients, parents and hospital staff is necessary

Thank you for you attention